The Board of Directors of Glenmark Pharmaceuticals Limited at its meeting held on 24th May, 2024, recommended Dividend at 250% i.e. INR 2.5/- per share (face value of INR 1/- each) on the Equity Share Capital of the Company for the financial year 2023-24 subject to the approval of the Shareholders at the up coming Annual General Meeting.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,237 INR | +1.00% | +3.60% | +44.87% |
Jun. 12 | India Equities Close Higher Ahead of US Inflation Data | MT |
Jun. 12 | Glenmark Pharmaceuticals Gets US FDA Final Nod for Esomeprazole Magnesium Capsules | MT |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+44.87% | 4.18B | |
+20.37% | 43.54B | |
+18.30% | 21.78B | |
+17.66% | 15.38B | |
+25.55% | 15.12B | |
+60.99% | 13.36B | |
-0.05% | 6.79B | |
-14.84% | 6.38B | |
-8.87% | 5.73B | |
+8.17% | 5.32B |
- Stock Market
- Equities
- GLENMARK Stock
- News Glenmark Pharmaceuticals Limited
- Glenmark Pharmaceuticals Limited Recommends Dividend for the Financial Year 2023-24